Aptevo Therapeutics surprised analysts with quarterly losses of $(1.420) per share on March 5, 2024, beating expectations by 17.44%. This financial performance was part of the company’s 3Q23 results, where they reported a net loss of $6.3 million or $0.50 per share for the three months ended September 30, 2023. Aptevo Therapeutics is set to release its earnings on April 4, 2024. In the second quarter of 2023, the company had cash and cash equivalents amounting to $21.0 million as of June 30, 2023.
APVO Stock Plummets 13.72% on March 5, 2024: What Investors Need to Know
On March 5, 2024, APVO stock experienced a significant drop in its price, closing at $0.14 per share, a decrease of $0.02 from the previous market close. This represents a 13.72% drop in the stock price, indicating a bearish trend for the day.
APVO Stock Analysis: Strong Performance and Positive Growth Trends on March 5, 2024
On March 5, 2024, APVO stock showed strong performances based on the financial data provided. Despite the lack of information on total revenue, the company’s net income figures indicate positive growth trends. APVO reported a net income of $8.03 million over the past year, which is a significant increase of 128.21% compared to the previous year. The net income for the third quarter was -$6.33 million, showing an improvement of 20.31% compared to the previous quarter. The earnings per share (EPS) for APVO also showed impressive growth, with the EPS for the past year at $1.57, marking an increase of 125.91% compared to the previous year. The EPS for the third quarter was -$0.50, but still showed a substantial improvement of 58.93% compared to the previous quarter. Overall, the financial data for APVO on March 5, 2024, paints a positive picture of the company’s performance, with increasing net income and earnings per share suggesting a growth trajectory. Investors may want to keep an eye on this stock as it continues to show promising financial results.
